Evidence Snapshot

Androgen receptor

CHEMBL1871 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:21Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:30 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1871

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Androgen receptor as ChEMBL target CHEMBL1871, mapped to UniProt P10275. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Androgen receptor

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL1871

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P10275

Androgen receptor

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Androgen receptor matters

As of 2026-09-13

Androgen receptor is reviewed as Androgen receptor (UniProt P10275); Androgen receptor shows approved-linked disease relevance led by prostate cancer. 5 more disease programs remain visible in the same review block.; 19 linked drugs keep this evidence frame grounded.; the current evidence base includes 48 approved drugs, 6296 compounds, and 1518 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Androgen receptor

Androgen receptor Sequence length is 920 aa.

Review this target as Androgen receptor, mapped to UniProt P10275. Sequence length is 920 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P10275 Protein

Disease context

prostate cancer

Androgen receptor shows approved-linked disease relevance led by prostate cancer. 5 more disease programs remain visible in the same review block. 19 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ABIRATERONE, APALUTAMIDE, APC-100.

Start review with prostate cancer because it currently carries approved-linked support. Linked drugs include ABIRATERONE, APALUTAMIDE, APC-100, AZD3514. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 19 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 48 approved drugs, 6296 compounds, and 1518 assays for this target. The dominant activity type is IC50. CHEMBL180681 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL180681 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

48 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Androgen receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P10275, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why prostate cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

6296

Total Compounds

1518

Total Assays

Approved Drugs

IC50: 4424.0, KI: 1338.0, EC50: 940.0, KD: 36.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL180681	11.0	Ki	—
No preferred name CHEMBL166444	10.9	EC50	Clinical
No preferred name CHEMBL391548	10.7	IC50	—
No preferred name CHEMBL3818706	10.5	EC50	—
No preferred name CHEMBL3238292	10.4	EC50	—

Approved Drugs

Structure	Compound	First Approval
	CLASCOTERONE CHEMBL3590187	2020
	DAROLUTAMIDE CHEMBL4297185	2019
	APALUTAMIDE CHEMBL3183409	2018
	ENZALUTAMIDE CHEMBL1082407	2012
	DROSPIRENONE CHEMBL1509	2001
	MIFEPRISTONE CHEMBL1276308	2000
	NILUTAMIDE CHEMBL1274	1996
	BICALUTAMIDE CHEMBL409	1995
	DORZOLAMIDE CHEMBL218490	1994
	FLUTAMIDE CHEMBL806	1989
	PYRVINIUM CHEMBL1201303	1982
	PROGESTERONE CHEMBL103	1976
	ESTRADIOL CHEMBL135	1975
	TESTOSTERONE PROPIONATE CHEMBL1170	1974
	TESTOSTERONE CHEMBL386630	1972
	INDOMETHACIN CHEMBL6	1965
	OXANDROLONE CHEMBL1200436	1964
	SPIRONOLACTONE CHEMBL1393	1960
	MEDROXYPROGESTERONE ACETATE CHEMBL717	1959
	FLUOXYMESTERONE CHEMBL1445	1956

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:21Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:30 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL1871